A clear vision to prevent and reverse corneal blindness

Novel, first-in-class cornea gene therapy
RainBio is the only ocular gene therapy pioneer focused on blindness in the cornea. Our adeno-associated virus (AAV) vector gene therapy can directly correct cornea cellular function to maintain or restore vision in patients at risk of blindness from a number of diseases. Our groundbreaking first-in-class lead program for corneal clouding in Mucopolysaccharidosis type 1 (MPS1) patients who have vision loss from this rare genetic disease opens up a new field in ocular gene therapy.
Based in Raleigh, NC, RainBIO was founded by University of North Carolina and NC State University scientists and an experienced management team passionate about delivering the life-changing gift of sight to patients.
Ben Yerxa
Ben Yerxa, PhD
Chairman, RainBIO
CEO, Foundation Fighting Blindness
Matt Hirsch
Matt Hirsch, PhD
UNC-CH Associate Professor of Ophthalmology, Gene Therapy Center
Brian Gilger
Brian Gilger, DVM
NC State University
Professor of Ophthalmology
Fran Martin
Fran Martin, RPh